Meridian’s antibodies are highly sensitive for the detection of SARS-CoV-2 and they are ideal for developing reliable and sensitive rapid antigen assays for the detection of active COVID-19 infections. Meridian has a novel antibody pair to trimeric SARS-CoV-2 S1 protein that is capable of recognizing the spike 1 (S1) protein in saliva samples regardless of its confirmation state (e.g. “up” or “down”). The antibodies bind to a linear epitope on the S1 protein that is distinct from the RBD protein which has epitopes that are conformation-dependent. Recent studies have shown that linear epitopes on the S1 protein are able elicit neutralizing antibodies in COVID-19 patients and have potent antigenicity, making them prime targets for diagnostic, therapeutic and vaccine targets. Li, Y., Lai, D., Zhang, H. et al. Linear epitopes of SARS-CoV-2 spike protein elicit neutralizing antibodies in COVID-19 patients. Cell Mol Immunol (2020).